A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents

NCT ID: NCT00389519

Last Updated: 2012-06-11

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

422 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-10-31

Study Completion Date

2007-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this study is to evaluate the blood pressure lowering effects of ramipril, an FDA-approved drug for the treatment of hypertension in adults, in children and adolescents aged 6 to 16 years with hypertension.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Information is needed on the treatment of hypertension in children and adolescents with antihypertensive drugs like ramipril. The study will assess the safety and blood pressure effects of several doses of the antihypertensive drug ramipril in children and adolescents age 6-16 years. Approximately 450 children will be given placebo, or 1 of the 3 doses of ramipril. The treatment assigned will be done by chance, like flipping a coin. Approximately 120 study centers throughout the world will participate in the trial.

Each child will complete a 1- to 4-week Screening Period where they will stop taking their current blood pressure lowering drug(s), a 4-week Treatment Period where they will receive placebo or one of the ramipril doses, and a Follow-up visit 1 week after completion of the Treatment Period. Children diagnosed with hypertension according to the fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents (U.S. report), will be included in the study if their blood pressure meets certain values.

Each child will complete a minimum of 6 and up to 9 clinic visits over the course of the study during which procedures and assessments of blood pressure and safety will be performed. In addition, a child's parents/guardians will be instructed to measure their child's blood pressure at home between clinic visits.

A planned interim analysis was performed after approximately 240 subjects completed the trial. The study was stopped, as permitted by protocol, after the analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

once per day

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

once a day oral placebo capsule for 4 weeks

ramipril low dose

0.3125, 0.625, or 1.25 mg once a day, based on subject weight

Group Type EXPERIMENTAL

ramipril

Intervention Type DRUG

once a day oral ramipril capsules given for 4 weeks

ramipril mid dose

1.25, 2.5, or 5 mg once a day, based on subject weight

Group Type EXPERIMENTAL

ramipril

Intervention Type DRUG

once a day oral ramipril capsules given for 4 weeks

ramipril high dose

5, 10, or 20 mg once a day, based on subject weight

Group Type EXPERIMENTAL

ramipril

Intervention Type DRUG

once a day oral ramipril capsules given for 4 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ramipril

once a day oral ramipril capsules given for 4 weeks

Intervention Type DRUG

placebo

once a day oral placebo capsule for 4 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Altace

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Previous, documented diagnosis of hypertension, or newly diagnosed hypertension according to the fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents (United States). SiSBP greater than or equal to the 95th percentile for age, gender, and height.
2. The subject can be safely withdrawn from antihypertensive medications during the screening period, and if given placebo during the treatment period in the judgment of the Investigator.
3. The subject is male or female age 6 to 16 years (inclusive), and weighs greater than or equal to 20 kg.
4. Female subjects greater than or equal to 12 years of age, or who have had greater than or equal to 1 menstruation must: (a) have a negative serum pregnancy test at screening (i.e., subject is not pregnant), (b) not be lactating, and (c) use an acceptable method of contraception.
5. Parents/guardians are able to demonstrate their ability to (a) use a home blood pressure monitor supplied for the study to monitor their child's blood pressure, and (2) mix and administer a liquid dose of study drug if needed.

Exclusion Criteria

1. Bilateral renal artery stenosis.
2. Uncorrected coarctation of the aorta or corrected coarctation with a right arm/right leg blood pressure gradient greater than 10 mmHg.
3. Severe hypertension.
4. Renal transplantation or other previous solid organ transplantation less than 6 months prior to entering the study.
5. Subjects with nephrotic syndrome not on stable maintenance therapy of prednisone or cyclosporine.
6. A history of cardiomyopathy, clinically significant structural heart disease, or atrioventricular conduction disturbance, sick sinus syndrome, atrial flutter, atrial fibrillation, clinically significant bradycardia or an accessory bypass tract, or clinical symptoms of congestive heart failure.
7. Clinically significant hematologic, hepatobiliary, or renal disease including a Schwartz formula GFR less than 40 mL/min/1.73 m2, and/or serum potassium (K+) greater than 5.5 mEq/L.
8. History of pancreatitis (active or inactive).
9. Known sensitivity to angiotensin converting enzyme inhibitors or a history of angioneurotic edema.
Minimum Eligible Age

6 Years

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UAMS College of Medicine/ Arkansas Children's Hospital

Little Rock, Arkansas, United States

Site Status

Woodland International Research Group, LLC

Little Rock, Arkansas, United States

Site Status

Impact Clinical Research

Beverly Hills, California, United States

Site Status

Neufeld Medical Group

Los Angeles, California, United States

Site Status

Almon Clinical Research, Inc.

Orange, California, United States

Site Status

Pediatrics in Brevard

Cocoa Beach, Florida, United States

Site Status

Watson Clinic Center for Research, Inc.

Lakeland, Florida, United States

Site Status

Emory University

Atlanta, Georgia, United States

Site Status

Medical College of Georgia

Augusta, Georgia, United States

Site Status

Hawaii Pacific Health

Honolulu, Hawaii, United States

Site Status

Nephrology and Hypertension Consultants

Park Ridge, Illinois, United States

Site Status

Tinley Park Pediatric Associates

Tinley Park, Illinois, United States

Site Status

Kosair Children's Hospital

Louisville, Kentucky, United States

Site Status

Louisiana State University

Shreveport, Louisiana, United States

Site Status

Craig Spiegel, MD

Bridgeton, Missouri, United States

Site Status

Impact Clinical Trials

Las Vegas, Nevada, United States

Site Status

Children's Heart Center

Las Vegas, Nevada, United States

Site Status

Premier Clinical Research Group

Toms River, New Jersey, United States

Site Status

SUNY Upstate Syracuse, Department of Pediatrics

Syracuse, New York, United States

Site Status

Hartrich Aquino & Hrab, PC

Williamsville, New York, United States

Site Status

Western Wake Pediatrics

Cary, North Carolina, United States

Site Status

University of North Carolina

Chapel Hill, North Carolina, United States

Site Status

Duke Pediatric Clinical Research Program

Durham, North Carolina, United States

Site Status

North Carolina Children's and Adults Clinical Research Foundation

Sylva, North Carolina, United States

Site Status

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Site Status

Center for Clinical and Translational Research

Columbus, Ohio, United States

Site Status

Central Sooner Research

Norman, Oklahoma, United States

Site Status

The University of Oklahoma

Tulsa, Oklahoma, United States

Site Status

Oregon Health and Science University

Portland, Oregon, United States

Site Status

Northwest Pediatric Kidney Specialists, LLC

Portland, Oregon, United States

Site Status

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Holston Medical Group

Kingsport, Tennessee, United States

Site Status

Le Bonheur Children's Hospital

Memphis, Tennessee, United States

Site Status

South East Texas Cardiology Associates

Beaumont, Texas, United States

Site Status

University of Texas Medical Center

Houston, Texas, United States

Site Status

University of Utah

Salt Lake City, Utah, United States

Site Status

University of Virginia

Charlottesville, Virginia, United States

Site Status

Huguenot Pediatrics

Midlothian, Virginia, United States

Site Status

Children's Specialty Group

Norfolk, Virginia, United States

Site Status

Hospital de Niños "Dr. Ricardo Gutiérrez"

Buenos Aires, , Argentina

Site Status

Hospital General Interzonal "Dr. José Penna"

Buenos Aires, , Argentina

Site Status

Hospital Interzonal Especializado Materno Infantil

Buenos Aires, , Argentina

Site Status

Hospital Italiano de Buenos Aires

Buenos Aires, , Argentina

Site Status

Hospital de Niños Juan Carlos Navarro

San Juan, , Argentina

Site Status

Centro Infantil del Rínon

Tucomán, , Argentina

Site Status

Clínica Las Condes

Santiago, , Chile

Site Status

Hospital de Niños Roberto del Rio

Santiago, , Chile

Site Status

Hospital Luis Calvo Mackena

Santiago, , Chile

Site Status

Hospital Dr. Gustavo Fricke

Viña del Mar, , Chile

Site Status

Fundación Bios

Barranquilla, , Colombia

Site Status

Fundación Cardio Infantil - Instituto de Cardiología

Bogotá, , Colombia

Site Status

Hospital de San Jose

Bogotá, , Colombia

Site Status

Instituto Nacional del Riñón

Bogotá, , Colombia

Site Status

Hospital Pablo Tobon Uribe

Medellín, , Colombia

Site Status

Hospital Universitario San Vicente de Paul

Medellín, , Colombia

Site Status

Gujarat Kidney Foundation, Jivraj Mehta Hospital

Ahmedabad, , India

Site Status

Heart Care Clinic

Ahmedabad, , India

Site Status

St. John's Hospital

Bangalore, , India

Site Status

Institute of Child Health & Hospital for Children

Chennai, , India

Site Status

AIl India Institute medical sciences

Delhi, , India

Site Status

Apollo Hospital

Delhi, , India

Site Status

Maulana Azad Medical College and Lok Nayak Hospital

Delhi, , India

Site Status

Apollo Hospital Hyderabad

Hyderabaad, , India

Site Status

Nizam's Institute of Medical Sciences

Hyderabaad, , India

Site Status

Christian Medical College and Hospital

Ludhiana, , India

Site Status

Jaslok Hospital and Research Centre

Mumbai, , India

Site Status

KEM Hospital Research Centre

Pune, , India

Site Status

Kerala Institute of Medical Science

Trivandrum, , India

Site Status

Klinika Nefrologii Dzieciecej SPSK nr 1 ACK AMG

Gdansk, , Poland

Site Status

Katedra i Klinika Kardiologii Dzieciecej SK nr 6, Gornoslaskie Centrum Zdrowia Dziecka i Matki, Slaska AM

Katowice, , Poland

Site Status

II Katedra Pediatrii, Klinika Kardiologii Dzieciecej UM w Lodzi

Lodz, , Poland

Site Status

Klinika Nefrologii i Dializoterapii, Instytut Centrum Zdrowia Matki Polki

Lodz, , Poland

Site Status

Klinika Kardiologii i Nefrologii Dzieciecej AM

Poznan, , Poland

Site Status

I Klinika Chorob Dzieci SPSK nr 1 PAM

Szczecin, , Poland

Site Status

Oddzial Nefrologi Dzieciecej ze Stacja Dializ SSP ZOZ nad Dziecklem i Mlodzieza

Szczecin, , Poland

Site Status

Oddzial Pediatrii i Nefrologii ze Stacja Dializ, Wojewodzki Szpital Dzieciecy

Torun, , Poland

Site Status

Klinika Nefrologii i Transplantacji Nerek, Instytut Pomnik Centrum Zdrowia Dziecka

Warsaw, , Poland

Site Status

Klinika Nefrologii Pediatrycznej AM

Wroclaw, , Poland

Site Status

Benmed Park Clinic

Benoni, , South Africa

Site Status

Chris Hani Baragwanath

Johannesburg, , South Africa

Site Status

Global Clinical Trial Centre

Port Elizabeth, , South Africa

Site Status

Potchefstroom Medi-Clinic

Potchefstroom, , South Africa

Site Status

Eastmed Medical centre

Pretoria, , South Africa

Site Status

Jubilee CTC Jubilee Hospital

Pretoria, , South Africa

Site Status

Pretoria Academic Hospital

Pretoria, , South Africa

Site Status

Zuid Afrikaans Hospital

Pretoria, , South Africa

Site Status

Sandton Clinical Research Centre

Sandton, , South Africa

Site Status

Istanbul University Istanbul Medical Faculty Pediatric Nephrology

Istanbul, , Turkey (Türkiye)

Site Status

Marmara University Medical Faculty Pediatric Nephrology

Istanbul, , Turkey (Türkiye)

Site Status

Dokuzeylul University Medical Faculty Pediatric Nephrology

Izmir, , Turkey (Türkiye)

Site Status

Ondokummayis University Medical Faculty Pediatric Nephrology

Samsun, , Turkey (Türkiye)

Site Status

Dnepropetrovsk Medical Academy, Department of Hospital Pediatrics on the bases of Regional Pediatric Hospital

Dnipro, , Ukraine

Site Status

Kharkov State University,Dept. of hospital pediatric on the bases of Regional Children's Hospital

Kharkiv, , Ukraine

Site Status

NMU n.b. Bogomolets, on b.o. Chil. Clin.Hosp.#2, Department of Pediatrics #2

Kiev, , Ukraine

Site Status

Institute of Pediatrics and Obstetrics AMS of Ukraine, Department of ecology related health problems

Kyiv, , Ukraine

Site Status

Danylo Halytskiy Lviv NationalMedical University, Department of Faculty

Lviv, , Ukraine

Site Status

Odessa State Medical University, Dept. of hospital pediatric and neonotology on the bases of Regional Children Hospital

Odesa, , Ukraine

Site Status

Crim.St. Med. Uni. On b.o. Rep. Child.Clin.Hosp. Chair of Pediat. W.c. of Physioth. Of the Postgr.dept

Simferopol, , Ukraine

Site Status

Uzhorod National University, Medical faculty, Department of Children's disease with course of Infection disease on the basis of City Children's Clinical Hospital.

Uzhhorod, , Ukraine

Site Status

Vinnitsa National Medical Academy, Department of Hospital Pediatrics on the bases of Regional Pediatric Hospital

Vinnitsa, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Chile Colombia India Poland South Africa Turkey (Türkiye) Ukraine

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

K726-06-4003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ramipril - Hypertension
NCT00325806 COMPLETED PHASE4
Doxazosin and Ramipril in Hypertension
NCT02901977 COMPLETED PHASE4
Ramipril 10 mg/Day Prevention
NCT01053910 COMPLETED PHASE4